Weekly Research Analysts’ Ratings Changes for Sarepta Therapeutics (SRPT)

A number of firms have modified their ratings and price targets on shares of Sarepta Therapeutics (NASDAQ: SRPT) recently:

• 4/7/2026 – Sarepta Therapeutics had its price target raised by Royal Bank Of Canada from $18.00 to $19.00. They now have a “sector perform” rating on the stock.
• 3/26/2026 – Sarepta Therapeutics had its price target raised by Wedbush from $29.00 to $35.00. They now have an “outperform” rating on the stock.
• 3/26/2026 – Sarepta Therapeutics had its price target raised by Deutsche Bank Aktiengesellschaft from $12.00 to $14.00. They now have a “sell” rating on the stock.
• 3/26/2026 – Sarepta Therapeutics had its price target raised by Citigroup Inc. from $9.00 to $13.00. They now have a “sell” rating on the stock.
• 3/26/2026 – Sarepta Therapeutics had its “underperform” rating reaffirmed by Needham & Company LLC.
• 3/19/2026 – Sarepta Therapeutics had its “outperform” rating reaffirmed by Oppenheimer Holdings, Inc.. They now have a $37.00 price target on the stock.
• 3/12/2026 – Sarepta Therapeutics had its price target raised by Mizuho from $26.00 to $31.00. They now have an “outperform” rating on the stock.
• 3/10/2026 – Sarepta Therapeutics had its price target raised by Citigroup Inc. from $8.00 to $9.00. They now have a “sell” rating on the stock.
• 3/3/2026 – Sarepta Therapeutics was given a new $25.00 price target by Loop Capital.
• 3/3/2026 – Sarepta Therapeutics had its “buy” rating reaffirmed by Jefferies Financial Group Inc.. They now have a $30.00 price target on the stock.
• 3/2/2026 – Sarepta Therapeutics had its price target lowered by Wedbush from $34.00 to $29.00. They now have an “outperform” rating on the stock.
• 3/2/2026 – Sarepta Therapeutics had its “sell” rating reaffirmed by HC Wainwright.
• 2/28/2026 – Sarepta Therapeutics was upgraded by Wall Street Zen from “sell” to “hold”.
• 2/27/2026 – Sarepta Therapeutics had its price target lowered by Wells Fargo & Company from $45.00 to $38.00. They now have an “overweight” rating on the stock.

Insider Buying and Selling at Sarepta Therapeutics

In other Sarepta Therapeutics news, Director Stephen Mayo sold 7,239 shares of the company’s stock in a transaction that occurred on Thursday, March 12th. The stock was sold at an average price of $17.02, for a total transaction of $123,207.78. Following the completion of the sale, the director directly owned 1,765 shares of the company’s stock, valued at $30,040.30. This represents a 80.40% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 7.60% of the company’s stock.

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.